First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

BACKGROUND: Avelumab (anti-programmed death ligand 1 (PD-L1)) is approved in multiple countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and aggressive skin cancer. We report efficacy and safety data and exploratory biomarker analyses from a cohort of patients with mMCC t...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Immunother Cancer
Egile Nagusiak: D'Angelo, Sandra P, Lebbé, Celeste, Mortier, Laurent, Brohl, Andrew S, Fazio, Nicola, Grob, Jean-Jacques, Prinzi, Natalie, Hanna, Glenn J, Hassel, Jessica C, Kiecker, Felix, Georges, Sara, Ellers-Lenz, Barbara, Shah, Parantu, Güzel, Gülseren, Nghiem, Paul
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2021
Gaiak:
Clinical/Translational Cancer Immunotherapy
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8311489/
https://ncbi.nlm.nih.gov/pubmed/34301810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002646
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak